| Fatema S Uddin, MD | |
|
1301 Pennsylvania Ave, Fort Worth, TX 76104-2122 | |
| (817) 250-4906 | |
| (817) 250-1815 |
| Full Name | Fatema S Uddin |
|---|---|
| Gender | Female |
| Speciality | Gastroenterology |
| Experience | 18 Years |
| Location | 1301 Pennsylvania Ave, Fort Worth, Texas |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1144430893 | NPI | - | NPPES |
| 8GF861 | Other | TX | BLUE CROSS BLUE SHIELD |
| BP1-0026170 | Other | INSTITUTIONAL PERMIT |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RG0100X | Internal Medicine - Gastroenterology | N2326 (Texas) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Altru Hospital | Grand forks, ND | Hospital |
| U S M D Hospital At Arlington L P | Arlington, TX | Hospital |
| The Hospitals Of Providence Transmountain Campus | El paso, TX | Hospital |
| Entity Name | Gastroenterology Practice Associates, Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1821224825 PECOS PAC ID: 0143367342 Enrollment ID: O20091020000739 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.
The Autism Consortium, an innovative collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), held its fourth annual symposium on October 28th, 2009, at Harvard Medical School in Boston.
In a Huffington Post "Impact" blog post, Tom Murphy, founder of the development blog "A View From The Cave," examines Rwanda's efforts to reduce cancer incidence by implementing screening programs for breast and cervical cancers and vaccinating girls and young women for human papillomavirus (HPV), the leading cause of cervical cancer.
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
First results from a large tissue survey in Britain of the agent that causes variant Creutzfeldt-Jakob disease (vCJD) are unable so far to establish that the prevalence is lower than that given by previous estimates, concludes a study published on bmj.com.
› Verified 7 days ago
| Entity Name | Fatema S Uddin Md Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1205393279 PECOS PAC ID: 7719228410 Enrollment ID: O20190405002085 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.
The Autism Consortium, an innovative collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), held its fourth annual symposium on October 28th, 2009, at Harvard Medical School in Boston.
In a Huffington Post "Impact" blog post, Tom Murphy, founder of the development blog "A View From The Cave," examines Rwanda's efforts to reduce cancer incidence by implementing screening programs for breast and cervical cancers and vaccinating girls and young women for human papillomavirus (HPV), the leading cause of cervical cancer.
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
First results from a large tissue survey in Britain of the agent that causes variant Creutzfeldt-Jakob disease (vCJD) are unable so far to establish that the prevalence is lower than that given by previous estimates, concludes a study published on bmj.com.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Fatema S Uddin, MD 1301 Pennsylvania Ave, Fort Worth, TX 76104-2122 Ph: (817) 250-4906 | Fatema S Uddin, MD 1301 Pennsylvania Ave, Fort Worth, TX 76104-2122 Ph: (817) 250-4906 |
News Archive
OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.
The Autism Consortium, an innovative collaboration of researchers, clinicians, funders and families dedicated to catalyzing research and enhancing clinical care for autism spectrum disorders (ASDs), held its fourth annual symposium on October 28th, 2009, at Harvard Medical School in Boston.
In a Huffington Post "Impact" blog post, Tom Murphy, founder of the development blog "A View From The Cave," examines Rwanda's efforts to reduce cancer incidence by implementing screening programs for breast and cervical cancers and vaccinating girls and young women for human papillomavirus (HPV), the leading cause of cervical cancer.
Patients in early clinical trials of new-style targeted cancer therapies appear to have a much lower risk of the most serious side-effects than with traditional chemotherapy, according to a new analysis.
First results from a large tissue survey in Britain of the agent that causes variant Creutzfeldt-Jakob disease (vCJD) are unable so far to establish that the prevalence is lower than that given by previous estimates, concludes a study published on bmj.com.
› Verified 7 days ago
Charles A Carlton, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1622 8th Avenue, Suite 110, Fort Worth, TX 76104 Phone: 817-926-2561 Fax: 817-921-3708 | |
Paul J Garcia, DO Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 5701 Bryant Irvin Rd, Suite 302, Fort Worth, TX 76132 Phone: 817-294-9000 Fax: 817-294-9010 | |
Stevan A Gonzalez, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1250 8th Ave, Suite 515, Fort Worth, TX 76104 Phone: 817-922-4675 Fax: 817-922-4645 | |
Jeremy Aaron Ross, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 800 W Magnolia Ave, Fort Worth, TX 76104 Phone: 817-759-7000 Fax: 817-759-7027 | |
Elie B Choufani, M.D. Gastroenterology Medicare: Medicare Enrolled Practice Location: 601 W Terrell Ave, Fort Worth, TX 76104 Phone: 817-852-8305 | |
Syed Hadi Jafri, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1300 W Terrell Ave Fl 2, Fort Worth, TX 76104 Phone: 817-820-4906 Fax: 817-820-4815 | |
Cheryl K Mcdonald, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 1125 College Ave, Fort Worth, TX 76104 Phone: 817-810-9810 Fax: 817-810-9815 |